$170 Million is the total value of Stonepine Capital Management, LLC's 22 reported holdings in Q3 2017. The portfolio turnover from Q2 2017 to Q3 2017 was 83.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PCRX | New | PACIRA PHARMACEUTICALS INC | $14,089,000 | – | 375,200 | +100.0% | 8.30% | – |
| BDSI | Buy | BIODELIVERY SCIENCES INTL | $11,409,000 | +17.2% | 3,867,400 | +11.2% | 6.72% | +27.9% |
| APEN | New | APOLLO ENDOSURGERY INC | $11,067,000 | – | 2,364,707 | +100.0% | 6.52% | – |
| AVDL | Buy | AVADEL PHARMACEUTICALS PLCsponsored adr | $10,345,000 | +25.4% | 985,210 | +31.7% | 6.10% | +36.9% |
| BSTC | Buy | BIOSPECIFICS TECHNOLOGIES | $9,833,000 | +231.6% | 211,370 | +253.0% | 5.80% | +262.0% |
| CPIX | Buy | CUMBERLAND PHARMACEUTICALS | $8,982,000 | +15.7% | 1,272,191 | +14.7% | 5.29% | +26.3% |
| CRME | Buy | CARDIOME PHARMA CORP | $6,106,000 | -15.3% | 2,866,785 | +79.7% | 3.60% | -7.6% |
| OXFD | New | OXFORD IMMUNOTEC GLOBAL PLC | $2,726,000 | – | 162,286 | +100.0% | 1.61% | – |
| ICPT | New | INTERCEPT PHARMACEUTICALS IN | $1,080,000 | – | 18,600 | +100.0% | 0.64% | – |
| ALIM | Buy | ALIMERA SCIENCES INC | $644,000 | +150.6% | 477,226 | +158.2% | 0.38% | +173.4% |
| CBMX | New | COMBIMATRIX CORP | $475,000 | – | 63,283 | +100.0% | 0.28% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-11-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CTI Biopharmap Corp. | 24 | Q1 2023 | 14.8% |
| APOLLO ENDOSURGERY INC | 23 | Q1 2023 | 15.6% |
| XOMA CORP | 20 | Q3 2023 | 5.7% |
| Cumberland Pharmaceuticals, Inc. | 19 | Q4 2020 | 7.0% |
| Amarin Corp PLC - SPONS ADR | 14 | Q3 2022 | 23.2% |
| VANDA PHARMACEUTICALS INC | 14 | Q3 2023 | 20.9% |
| BIODELIVERY SCIENCES INTL | 14 | Q1 2020 | 12.9% |
| AFFIMED NV | 13 | Q3 2022 | 7.7% |
| ALIMERA SCIENCES INC | 13 | Q3 2019 | 4.2% |
| VIVEVE MEDICAL INC | 12 | Q2 2019 | 15.3% |
View Stonepine Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CTI BIOPHARMA CORP | April 13, 2023 | 7,018,046 | 5.3% |
| ADMA BIOLOGICS, INC. | February 13, 2023 | 6,940,000 | 3.1% |
| Amryt Pharma plc | February 13, 2023 | 31,666,195 | 9.9% |
| Apollo Endosurgery, Inc. | February 13, 2023 | 4,351,088 | 9.0% |
| Conformis Inc | February 13, 2023 | 748,194 | 9.9% |
| Ovid Therapeutics Inc.Sold out | February 13, 2023 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | February 14, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Conformis Inc | February 14, 2022 | 14,768,823 | 7.9% |
| YUMANITY THERAPEUTICS, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Stonepine Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-04-19 |
| 13F-HR | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View Stonepine Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.